Massimo Di Maio/X
Apr 12, 2025, 05:54
Massimo Di Maio: eNRGy trial – Making progress toward a future for NRG1 fusion-positive cancer
Massimo Di Maio, Director of the Genitourinary cancer Unit at National Cancer Institute Foundation, shared on X:
“Have a look at our viewpoint about the eNRGy trial, testing zenocutuzumab’s efficacy in patients with advanced cancer with NRG1 fusion.
Anyone clicking on the link before May 31, 2025 will be free to read or download the article.”
“eNRGy: Making progress toward a future for NRG1 fusion-positive cancer.”
Authors: Lucia Anna Muscarella, Massimo Di Maio
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 9, 2025, 11:22
May 9, 2025, 11:20
May 9, 2025, 11:01
May 9, 2025, 10:55
May 9, 2025, 10:37